Your browser doesn't support javascript.
Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a 5-year follow-up study.
Cheon, Shinhye; Park, Uni; Park, Hyoree; Kim, Yuri; Nguyen, Yen Thi Hai; Aigerim, Abdimadiyeva; Rhee, Ji-Young; Choi, Jae-Phil; Park, Wan Beom; Park, Sang Won; Kim, Yeonjae; Lim, Dong-Gyun; Yang, Jeong-Sun; Lee, Joo-Yeon; Kim, Yeon-Sook; Cho, Nam-Hyuk.
  • Cheon S; Division of Infectious Diseases, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
  • Park U; Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Park H; Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Kim Y; Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea; Institute of Endemic Disease, Seoul National University Medical Research Center, Seoul, Republic of Korea.
  • Nguyen YTH; Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Aigerim A; Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Rhee JY; Division of Infectious Diseases, Department of Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea.
  • Choi JP; Department of Internal Medicine, Seoul Medical Center, Seoul, Republic of Korea.
  • Park WB; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Park SW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Kim Y; Center for Infectious Diseases, National Medical Center, Seoul, Republic of Korea.
  • Lim DG; Center for Chronic Diseases, Research Institute, National Medical Center, Seoul, Republic of Korea.
  • Yang JS; Center for Emerging Virus Research, National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju-si, Republic of Korea.
  • Lee JY; Center for Emerging Virus Research, National Institute of Health, Korea Disease Control & Prevention Agency, Cheongju-si, Republic of Korea.
  • Kim YS; Division of Infectious Diseases, Chungnam National University School of Medicine, Daejeon, Republic of Korea. Electronic address: alice@cnuh.co.kr.
  • Cho NH; Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea; Institute of Endemic Disease, Seoul National University Medical Research C
Clin Microbiol Infect ; 28(2): 292-296, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1312375
ABSTRACT

OBJECTIVES:

We aimed to assess the longevity of spike-specific antibody responses and neutralizing activity in the plasma of recovered Middle East respiratory syndrome (MERS) patients.

METHODS:

We traced the antibody responses and neutralizing activity against MERS coronavirus (MERS-CoV) in peripheral blood samples collected from 70 recovered MERS patients for 5 years after the 2015 MERS outbreak in South Korea. We also measured the half-life of neutralizing antibody titres in the longitudinal specimens.

RESULTS:

The seropositivity rate persisted for up to 4 years (50.7-56.1%), especially in MERS patients who suffered from severe pneumonia, and then decreased (35.9%) in the fifth year. Although the spike-specific antibody responses decreased gradually, the neutralizing antibody titres decreased more rapidly (half-life 20 months) in 19 participants without showing negative seroconversion during the study period. Only five (26.3%) participants had neutralizing antibody titres greater than 1/1000 of PRNT50, and a high neutralizing antibody titre over 1/5000 was not detected in the participants at five years after infection.

DISCUSSION:

The seropositivity rate of the recovered MERS patients persisted up to 4 years after infection and significantly dropped in the fifth year, whereas the neutralizing antibody titres against MERS-CoV decreased more rapidly and were significantly reduced at 4 years after infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus Infections / Middle East Respiratory Syndrome Coronavirus Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Coronavirus Infections / Middle East Respiratory Syndrome Coronavirus Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2022 Document Type: Article